Skip to content
Screener

Aclaris Therapeutics ACRS Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$2.0MBeat by $674.3K
EPS-$0.15Beat by $0.01
Revenue estimate$1.3M
EPS estimate-$0.16

Next report

Nov 5, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$0.16

Financials

Q1 2026

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$454.08M+174%
Enterprise value$427.4M+211%
P/S54.3×+45.0×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Segments

By product

See full
Dermatology Therapeutics$1.5M—
Contract Research$537.0K—

By segment

See full
Single Reportable$2.0M—

FAQ

When did Aclaris Therapeutics report Q1 2026 earnings?
Aclaris Therapeutics (ACRS) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Aclaris Therapeutics's Q1 2026 revenue and EPS?
Aclaris Therapeutics reported revenue of $2.0M and eps of $-0.15 for Q1 2026.
Did Aclaris Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.3M by $674.3K. EPS beat the consensus estimate of $-0.16 by $0.01.
How did Aclaris Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.2% from $1.5M a year earlier and eps declined 25.0% from $-0.12.
Where can I find Aclaris Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-056669) and the 10-Q periodic report (0001104659-26-057202) directly on SEC EDGAR. The filing index links above go to sec.gov.